Loading
A phase 3 trial in lung cancer, run by Cell>Point LLC, not yet recruiting.
A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer is a phase 3, interventional study registered as NCT01394679 by Cell>Point LLC, with a registry enrolment figure of 154 participants, started 2025-05-01 and due to reach its primary completion in 2025-12. Interventions recorded: (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose); 18 F FDG followed by PET/CT imaging. Conditions listed: Lung Cancer. Primary outcome: Efficacy:Comparison of 99mTc-EcC-DG SPECT/CT images to 18F-FDG PET/CT images of primary lung cancer lesion and metastatic lesions. Lung eligibility wording from the registry: "The patient has had a non incisional biopsy demonstrating definitive evidence for lung cancer OR have clinical evidence and CT scan results consistent with a diagnosis of lung cancer". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Lung cancer (all types) and the tag lung-deep-dive.